Cystic Fibrosis

Cystic fibrosis (CF) is an inherited genetic disease affecting approximately 100,000 people worldwide, caused by mutations in the CFTR gene (cystic fibrosis transmembrane conductance regulator). The condition is inherited in an autosomal recessive pattern—a person needs two copies of a mutated CFTR gene (one from each parent) to have the disease, while carriers with one mutated copy typically have no symptoms. The CFTR gene provides instructions for making a protein that regulates the movement of salt (chloride) and water in and out of cells. When this protein doesn't work properly, it causes thick, sticky mucus to build up in multiple organs, particularly the lungs and digestive system. In healthy lungs, thin mucus traps bacteria and particles, which tiny hair-like structures (cilia) sweep out of airways. In CF, the abnormal mucus is too thick to clear effectively, creating an environment where bacteria thrive, leading to chronic infections, inflammation, and progressive lung damage. The same thick secretions block pancreatic ducts, preventing digestive enzymes from reaching the intestines, which causes malnutrition and difficulty absorbing fats and fat-soluble vitamins. CF also affects the sinuses, liver, reproductive organs, and sweat glands (unusually salty sweat is a characteristic sign). Over 2,000 different CFTR mutations have been identified, with the most common being F508del, accounting for about 70% of CF chromosomes worldwide. Different mutations affect the CFTR protein in different ways—some prevent it from being made, others cause it to fold incorrectly, reach the cell surface improperly, or function inadequately once in position.

Treatment has traditionally focused on managing symptoms and complications through a demanding daily regimen. Airway clearance techniques using chest physiotherapy, vibrating vests, or breathing devices help loosen and clear mucus from lungs—typically performed 1-2 times daily for 20-30 minutes. Inhaled medications include mucolytics (like dornase alfa) that thin mucus, hypertonic saline to draw water into airways, and antibiotics (inhaled, oral, or intravenous) to control bacterial infections. Pancreatic enzyme supplements taken with every meal and snack replace the digestive enzymes that can't reach the intestines, and fat-soluble vitamin supplements address deficiencies. Anti-inflammatory medications and medications to open airways are often prescribed. The most transformative advance has been CFTR modulator drugs that address the underlying genetic defect rather than just symptoms. Ivacaftor (Kalydeco) was first approved in 2012 for specific mutations, helping the defective CFTR protein function better. This was followed by combination therapies: lumacaftor/ivacaftor, then tezacaftor/ivacaftor, and most significantly, the triple combination elexacaftor/tezacaftor/ivacaftor (Trikafta), which addresses the most common F508del mutation. These modulators have dramatically improved lung function, reduced infections, improved nutrition, and transformed quality of life for eligible patients—some describe it as life-changing. For advanced lung disease, lung transplantation offers life extension, though it requires lifelong immunosuppression and doesn't cure CF (other organs remain affected).

Despite revolutionary CFTR modulators, approximately 10-15% of people with CF have mutations that don't respond to currently available drugs, leaving them without disease-modifying treatments and relying solely on symptom management. Even among those benefiting from modulators, the drugs don't restore completely normal CFTR function—lung function improves significantly but doesn't normalize, and progressive lung damage continues, albeit more slowly. Modulators don't reverse existing structural lung damage from years of disease before treatment availability. The daily treatment burden remains substantial even with modulators—airway clearance, multiple medications, frequent medical appointments, and monitoring continue, though the intensity may reduce. Chronic infections with difficult organisms like Pseudomonas aeruginosa, Burkholderia cepacia complex, and nontuberculous mycobacteria remain challenging to eradicate and can cause persistent lung inflammation despite antibiotics. Some bacteria develop antibiotic resistance, limiting treatment options. CF-related diabetes, liver disease, bone disease, and other complications require additional management. Modulator side effects including liver enzyme elevations, cataracts, and drug interactions affect some patients. Cost and access barriers prevent many people worldwide from obtaining CFTR modulators, which are among the most expensive medications available. The psychosocial burden of living with a chronic, life-limiting disease affects mental health, relationships, education, and career opportunities. Better methods to predict individual disease progression and treatment response would enable more personalized care approaches.

Next-generation CFTR modulators designed to work for mutations that don't respond to current drugs are in Phase 2 and Phase 3 trials, including drugs targeting nonsense mutations (where protein production stops prematurely) and other rarer mutation classes. Several compounds aim to amplify CFTR function beyond what current triple therapy achieves, potentially benefiting even those already on modulators. Combination approaches pairing new modulators with existing ones are being tested. Novel antibiotics and antibiotic combinations for resistant bacteria including inhaled and oral formulations are in advanced trials. Anti-inflammatory therapies targeting specific inflammatory pathways (including drugs that have shown success in other inflammatory lung diseases) are being evaluated to reduce lung damage from chronic inflammation. Mucolytic agents with improved properties are in testing. Drugs targeting bacterial virulence factors that make infections harder to clear are advancing through trials. CFTR amplifier drugs that increase the amount of CFTR protein made by cells are in clinical development. Gene therapy approaches delivering working copies of the CFTR gene to airway cells using viral vectors or non-viral delivery methods are in early clinical trials after years of preclinical development—while previous gene therapy attempts in the 1990s-2000s faced challenges, newer delivery methods and vectors show more promise.

mRNA therapy delivering temporary instructions for cells to produce functional CFTR protein is being developed, potentially offering an alternative to permanent gene therapy with the advantage of repeated dosing to maintain effect. CRISPR gene editing to correct CFTR mutations directly in airway cells represents a potential cure approach, with researchers working to overcome delivery challenges and ensure safety. Scientists are developing improved viral vectors and non-viral delivery systems (including nanoparticles and lipid-based carriers) to get genetic therapies into the difficult-to-reach airway cells efficiently. Stem cell approaches including generating healthy airway cells in the laboratory for transplantation or stimulating lung regeneration are in early research. Researchers are investigating drugs that bypass CFTR entirely by activating alternative chloride channels that could compensate for the defective CFTR protein—if successful, these would work regardless of CFTR mutation type. Scientists are exploring therapies targeting the excessive inflammation in CF lungs through novel anti-inflammatory approaches. Bacteriophage therapy using viruses that specifically kill problem bacteria is being investigated as an alternative to traditional antibiotics for resistant infections. Researchers are developing biomarkers beyond lung function tests—including specific proteins, genetic markers, and imaging signatures—that could detect lung damage earlier and track treatment response more precisely. Artificial intelligence is being applied to predict disease progression, identify patients at risk for rapid decline, and optimize treatment timing. Scientists are studying the lung microbiome (the community of bacteria and other microorganisms in airways) to understand which bacterial communities are associated with better or worse outcomes and whether microbiome modulation could improve health. Drugs that enhance bacterial killing by immune cells or that disrupt bacterial biofilms (protective structures bacteria build) are in development. Researchers are investigating whether restoring normal mucus properties through mechanisms independent of CFTR could provide therapeutic benefit. Lung tissue engineering and regenerative medicine approaches are in very early research as potential future alternatives to transplantation.